Novavax Inc (NASDAQ:NVAX)
During the Trading Day
| 2.04 |  -0.01 / -0.49% |
Data as of 4:00pm ET | Day’s Change |
During After-Hours Switch to standard view »
| 2.04 |  0.00 / 0.00% |
Volume: 84.3K |
Latest NVAX News | Press Releases
No recent news for Novavax Inc.
Today’s Trading
| Previous close | 2.05 |
| Today’s open | 2.01 |
| Day’s range | 1.98 - 2.08 |
| Volume | 1,152,550 |
| Average volume (3 months) | 1,456,293 |
| Market cap | $312.6M |
| Dividend yield | -- |
Data as of 4:00pm ET, 05/23/2013
Growth & Valuation
| Earnings growth (last year) | -29.41% |
| Earnings growth (this year) | -7.58% |
| Earnings growth (next 5 years) | 0.00% |
| Revenue growth (last year) | +50.30% |
| P/E ratio | NM |
| Price/Sales | 11.28 |
| Price/Book | 3.78 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| CRISCuris Inc | +0.08 | +2.16% |
| OSIROsiris Therapeutics ... | +0.09 | +0.82% |
| BTXBioTime Inc | -0.05 | -1.18% |
| OVASOvaScience Inc | -0.50 | -4.17% |
Data as of 4:01pm ET, 05/23/2013
Financials
| Next reporting date | August 9, 2013 |
| EPS forecast (this quarter) | -$0.06 |
| Annual revenue (last year) | $22.1M |
| Annual profit (last year) | -$28.5M |
| Net profit margin | -129.13% |
Profile
Sector Health Technology |
Industry Biotechnology |
President, Chief Executive Officer & Director Stanley C. Erck, MBA |
Vice President-Clinical & Medical Affairs Louis F. Fries, III, MD |
Corporate headquarters Rockville, Maryland |
Forecasts
